These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10568893)

  • 21. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
    ; ;
    Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
    James JS
    AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current challenges in the development of new treatments for lupus.
    Dall'Era M; Bruce IN; Gordon C; Manzi S; McCaffrey J; Lipsky PE
    Ann Rheum Dis; 2019 Jun; 78(6):729-735. PubMed ID: 30636212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Food and Drug Administration guidance: supervisory responsibilities of investigators.
    Anderson C; Young PA; Berenbaum A
    J Diabetes Sci Technol; 2011 Mar; 5(2):433-8. PubMed ID: 21527116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abetimus sodium: a medication for the prevention of lupus nephritis flares.
    Horowitz DM; Furie RA
    Expert Opin Pharmacother; 2009 Jun; 10(9):1501-7. PubMed ID: 19505217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal.
    Tselios K; Koumaras C; Urowitz MB; Gladman DD
    Semin Arthritis Rheum; 2014 Feb; 43(4):521-5. PubMed ID: 23953498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(179):49583-98. PubMed ID: 10185190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory issues for evaluation of therapies to prevent or arrest disease progression.
    Hyman FN; Welch ME; Cheever JR
    Ann Periodontol; 1997 Mar; 2(1):166-79. PubMed ID: 9151552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
    Itani KM; Shorr AF
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
    Basch E; Trentacosti AM; Burke LB; Kwitkowski V; Kane RC; Autio KA; Papadopoulos E; Stansbury JP; Kluetz PG; Smith H; Justice R; Pazdur R
    Cancer; 2014 Mar; 120(5):761-7. PubMed ID: 24375398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
    Runkel L; Stacey J
    Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials.
    Bertsias G; Gordon C; Boumpas DT
    Lupus; 2008 May; 17(5):437-42. PubMed ID: 18490423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
    Khin NA; Kronstein PD; Yang P; Ishida E; Hung HM; Mathis MV; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.